GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Century Therapeutics Inc (NAS:IPSC) » Definitions » Price-to-Owner-Earnings

Century Therapeutics (Century Therapeutics) Price-to-Owner-Earnings : (As of May. 15, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Century Therapeutics Price-to-Owner-Earnings?

As of today (2024-05-15), Century Therapeutics's share price is $3.09. Century Therapeutics does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Century Therapeutics's Price-to-Owner-Earnings or its related term are showing as below:


IPSC's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 34.09
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-05-15), Century Therapeutics's share price is $3.09. Century Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-2.21. Therefore, Century Therapeutics's PE Ratio for today is At Loss.

As of today (2024-05-15), Century Therapeutics's share price is $3.09. Century Therapeutics's EPS without NRI for the trailing twelve months (TTM) ended in was $-1.89. Therefore, Century Therapeutics's PE Ratio without NRI for today is At Loss.


Century Therapeutics Price-to-Owner-Earnings Historical Data

The historical data trend for Century Therapeutics's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Century Therapeutics Price-to-Owner-Earnings Chart

Century Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
- - - - -

Century Therapeutics Quarterly Data
Jun19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Century Therapeutics's Price-to-Owner-Earnings

For the Biotechnology subindustry, Century Therapeutics's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Century Therapeutics's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Century Therapeutics's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Century Therapeutics's Price-to-Owner-Earnings falls into.



Century Therapeutics Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Century Therapeutics's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=3.09/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Century Therapeutics  (NAS:IPSC) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Century Therapeutics Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Century Therapeutics's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Century Therapeutics (Century Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
3675 Market Street, Philadelphia, PA, USA, 19104
Century Therapeutics Inc is a biotechnology company developing transformative allogeneic cell therapies to create products for the treatment of both solid tumor and hematological malignancies with a significant unmet medical need. It is assembling a portfolio of allogeneic iNK and iT cell therapy product candidates across solid tumor and hematological malignancies.
Executives
Luis Borges officer: Chief Scientific Officer TWO CORPORATE DRIVE, C/O FIVE PRIME THERAPEUTICS, INC., SOUTH SAN FRANCISCO CA 94080
Timothy P Walbert director 1033 SKOKIE BOULEVARD, SUITE 355, NORTHBROOK IL 60062
Daphne Quimi director C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Versant Venture Capital Vi, L.p. 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Joseph Jimenez director ADITUM BIO, 1111 BROADWAY, STE. 1300, OAKLAND CA 94607
Eli Casdin director 1350 AVENUE OF THE AMERICAS, SUITE 1140, NEW YORK NY 10019
Cynthia M Butitta director 3165 PORTER DRIVE, PALO ALTO CA 94304
Kimberly Blackwell director C/O ZENTALIS PHARMACEUTICALS, LLC, 530 SEVENTH AVENUE, SUITE 2201, NEW YORK NY 10018
Rizzuto Carlo director ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Alessandro Riva director C/O CENTURY THERAPEUTICS, INC., 3675 MARKET STREET, PHILADELPHIA PA 19104
Hyam Levitsky officer: President of R&D C/O ANTIGENICS INC., 162 FIFTH AVE., SUITE 900, NEW YORK NY 10010
Adrienne Farid officer: Chief Operations Officer C/O CENTURY THERAPEUTICS, INC., 3675 MARKET STREET, PHILADELPHIA PA 19104
Gregory Russotti officer: Chief Technology Officer C/O CENTURY THERAPEUTICS, INC., 3675 MARKET STREET, PHILADELPHIA PA 19104
Osvaldo Flores officer: Chief Executive Officer C/O CENTURY THERAPEUTICS, INC., 3675 MARKET STREET, PHILADELPHIA PA 19104
Douglas Carr officer: VP of Finance and Operations C/O CENTURY THERAPEUTICS, INC., 3675 MARKET STREET, PHILADELPHIA PA 19104

Century Therapeutics (Century Therapeutics) Headlines

From GuruFocus